1.80 0.00 (0.00%)
Pre-Market: 8:00AM EDT
|Bid||1.76 x 1500|
|Ask||1.80 x 600|
|Day's Range||1.76 - 1.87|
|52 Week Range||0.67 - 6.96|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! MannKind Corporation (NASDAQ: MNKD ) stock was trading ...
MannKind Corporation (MNKD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Shares of MannKind Corp. sank 15% in premarket trade Friday, after the maker of inhaled therapeutic products announced a direct offering of 14 million shares, and warrants to buy an additional 14 million ...
February's wild ride has ended with the S&P 500 recovering most of a 10.10% correction to close down 2.82%. Here are four managers who did well in the most volatile, down month we've seen in a long time.
On a per-share basis, the Westlake Village, California-based company said it had a loss of 28 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. For the year, the company ...
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of David M. Kendall, MD, as Chief Medical Officer, effective February 12. Dr. Kendall will assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity.
Nate Pile's position in Nvidia appreciated 74% last year making his weighting in semiconductor stocks uncomfortably large. Recently, Nate trimmed his position in Nvidia and bought more MannKind, Apple, and Celgene.
Last year, prospects for Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) looked promising, until markets grew risk-adverse for small-cap biotechnology companies. Are bears right in betting against Synergy stock? Bears are sitting on gains with their 30.5% short float position in SGYP stock.
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.